Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcin...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
CONTACT
855-907-3286Clinical.Trials@bms.comFirst line of the email MUST contain NCT # and Site #.
CONTACT
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT07493044 · Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
NCT07176650 · Hepatocellular Carcinoma (HCC)
NCT07469319 · Hepatocellular Carcinoma (HCC), Cirrhosis
NCT07365930 · Hepatocellular Carcinoma (HCC)
NCT07178587 · Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)
Local Institution - 0070
Los Angeles, California
Local Institution - 0107
Chicago, Illinois
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions